I knew when I read the WSJ report yesterday covering Sanofi's Elias Zerhouni's remarks on the translation process from "bench to bedside" being "more difficult" then he thought that Derek Lowe would notice. His post this morning in the In the Pipeline blog therefore didn't disappoint me.
Predictably we can conclude that it IS a lot harder than it looks. What's more? it isn't going to be easy to fix, and coming up with a new model isn't too simple either. Undoubtedly casting a wider net beyond the walls of Sanofi's own R&D group (so-called "open innovation") will help, but by how much? We'll see -- and as noted yesterday -- it will be interesting to note if "outside collaboration" will include working with NIH's new translational medicine group or not.
Posted by Bruce Lehr May 24th 2011.